![Alexey Eliseev](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Alexey Eliseev
Fondateur chez
MirImmune, Inc.
Profil
Alexey V.
Eliseev is the founder of AC Immune SA, founded in 2003.
Dr. Eliseev is the founder of Alantos Pharmaceuticals AG, founded in 1999.
Dr. Eliseev is the founder of MirImmune, Inc., founded in 2015, and holds the titles of President, Treasurer & Director at MirImmune, Inc. Dr. Eliseev is also the founder of Boston BioCom LLC..
Dr. Eliseev is currently a Director at Bionevia Pharmaceuticals, Inc. Dr. Eliseev is Managing Director at Maxwell Asset Management LLC (US) since 2009.
Dr. Eliseev is Managing Director at Maxwell Asset Management LLC (Private Equity).
Formerly, Dr. Eliseev was Vice President at Biocom, Inc. Dr. Eliseev was Chief Business Officer at Phio Pharmaceuticals Corp.
in 2017.
Dr. Eliseev earned an MBA from Massachusetts Institute of Technology in 2005.
Dr. Eliseev earned a doctorate from Moscow State University Lomonosov in 1991.
Postes actifs de Alexey Eliseev
| Sociétés | Poste | Début |
|---|---|---|
Maxwell Asset Management LLC (US)
 Maxwell Asset Management LLC (US) Investment ManagersFinance Maxwell Asset Management manages the Maxwell Biotech Venture Fund. The fund focuses on investments in the biotechnology and pharmaceutical sectors with emphasis on therapeutics, industrial biotechnology and agricultural/veterinary applications. Within the therapeutics industry, the Fund focuses on investments in clinical areas of oncology, diseases of the central nervous system and metabolic disorders. The Fund invests in the application of biotechnology for industrial purposes including the production of biofuels and industrial reagents. In addition, the Fund invests in the application of biotechnology to strategically important agricultural products, such as plant growth promoters, crop protectors and animal health products. The Fund invests in public and private companies in North America, Europe and other parts of the world. Maxwell looks for companies: (1) that are developing products and technologies that are synergistic with the Fund's existing portfolio companies (2) with products that can benefit from testing in Russian clinical trial centers and (3) are interested in commercializing innovative therapeutics in the Russian market. The Maxwell Biotech Venture Fund's primary goal is to invest in Russian-based companies that are developing innovative products and technologies for the domestic and global markets. Maxwell also works with and invests in Western companies when they can help them advance their products along the development path, bring innovative products to the Russian market and generate superior return on investment. Typical investments range from $1 million to $10 million per company, depending on the stage of the company and its products. Maxwell is open to syndication with other venture firms. They place priority on investments that are likely to lead to a financial exit within 5 years. | Directeur en chef des Investissements | 06/01/2010 |
Maxwell Asset Management LLC (Private Equity)
 Maxwell Asset Management LLC (Private Equity) Investment ManagersFinance Maxwell Asset Management is an active manager which provides equity financing in companies located in Russia. The firm targets companies operating in the life sciences sector with a focus on biotechnology, therapeutics, and high-tech medical devices. It invests in early-stage capital requirements with an investment amount of up to USD 5 million in a single company. | Private Equity Investor | - |
MirImmune, Inc.
 MirImmune, Inc. BiotechnologyHealth Technology Develops immunotherapies for cancer treatment | Fondateur | 18/05/2015 |
Bionevia Pharmaceuticals, Inc.
 Bionevia Pharmaceuticals, Inc. Hospital/Nursing ManagementHealth Services Operates as a chronic disease hospital | Directeur/Membre du Conseil | - |
Anciens postes connus de Alexey Eliseev
| Sociétés | Poste | Fin |
|---|---|---|
| PHIO PHARMACEUTICALS CORP. | Corporate Officer/Principal | 15/09/2017 |
Alantos Pharmaceuticals AG
 Alantos Pharmaceuticals AG BiotechnologyHealth Technology Develops and manufactures molecule pharmaceuticals for arthritic and metabolic diseases | Fondateur | 31/12/2006 |
Boston BioCom LLC
 Boston BioCom LLC Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company, which develops and markets drugs | Fondateur | - |
| AC IMMUNE SA | Fondateur | - |
BIOCOM
 BIOCOM Miscellaneous Commercial ServicesCommercial Services Provides scientific and technological services | Corporate Officer/Principal | - |
Formation de Alexey Eliseev
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
82
Relations au 1er degré
11
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 11 |
|---|---|
AC Immune SA
 AC Immune SA Pharmaceuticals: MajorHealth Technology Manufactures precision medicines for neurodegenerative diseases | Health Technology |
Massachusetts Institute of Technology
 Massachusetts Institute of Technology Finance/Rental/LeasingFinance Functions as a College/University | Finance |
Moscow State University Lomonosov
 Moscow State University Lomonosov Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Alantos Pharmaceuticals AG
Alantos Pharmaceuticals AG BiotechnologyHealth Technology Develops and manufactures molecule pharmaceuticals for arthritic and metabolic diseases | Health Technology |
BIOCOM
BIOCOM Miscellaneous Commercial ServicesCommercial Services Provides scientific and technological services | Commercial Services |
Bionevia Pharmaceuticals, Inc.
Bionevia Pharmaceuticals, Inc. Hospital/Nursing ManagementHealth Services Operates as a chronic disease hospital | Health Services |
Maxwell Asset Management LLC (US)
Maxwell Asset Management LLC (US) Investment ManagersFinance Maxwell Asset Management manages the Maxwell Biotech Venture Fund. The fund focuses on investments in the biotechnology and pharmaceutical sectors with emphasis on therapeutics, industrial biotechnology and agricultural/veterinary applications. Within the therapeutics industry, the Fund focuses on investments in clinical areas of oncology, diseases of the central nervous system and metabolic disorders. The Fund invests in the application of biotechnology for industrial purposes including the production of biofuels and industrial reagents. In addition, the Fund invests in the application of biotechnology to strategically important agricultural products, such as plant growth promoters, crop protectors and animal health products. The Fund invests in public and private companies in North America, Europe and other parts of the world. Maxwell looks for companies: (1) that are developing products and technologies that are synergistic with the Fund's existing portfolio companies (2) with products that can benefit from testing in Russian clinical trial centers and (3) are interested in commercializing innovative therapeutics in the Russian market. The Maxwell Biotech Venture Fund's primary goal is to invest in Russian-based companies that are developing innovative products and technologies for the domestic and global markets. Maxwell also works with and invests in Western companies when they can help them advance their products along the development path, bring innovative products to the Russian market and generate superior return on investment. Typical investments range from $1 million to $10 million per company, depending on the stage of the company and its products. Maxwell is open to syndication with other venture firms. They place priority on investments that are likely to lead to a financial exit within 5 years. | Finance |
Boston BioCom LLC
Boston BioCom LLC Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company, which develops and markets drugs | Health Technology |
Phio Pharmaceuticals Corp.
 Phio Pharmaceuticals Corp. BiotechnologyHealth Technology Develops RNAi-based medical technologies and therapies | Health Technology |
Maxwell Asset Management LLC (Private Equity)
Maxwell Asset Management LLC (Private Equity) Investment ManagersFinance Maxwell Asset Management is an active manager which provides equity financing in companies located in Russia. The firm targets companies operating in the life sciences sector with a focus on biotechnology, therapeutics, and high-tech medical devices. It invests in early-stage capital requirements with an investment amount of up to USD 5 million in a single company. | Finance |
MirImmune, Inc.
MirImmune, Inc. BiotechnologyHealth Technology Develops immunotherapies for cancer treatment | Health Technology |
